Researcher
Kathelijne Peerlinck
- Disciplines:Cardiac and vascular medicine, Molecular and cell biology
Affiliations
- Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2021
Projects
1 - 4 of 4
- Genome medicine for bleeding, thrombotic and platelet disordersFrom1 Oct 2019 → 30 Sep 2023Funding: BOF - projects
- Quantification of joint loading in adults with haemophilia using multi-segment foot modellingFrom1 Mar 2018 → 8 Sep 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- Biomechanische determinanten en patronen geassocieerd aan de pathophysiologische enkelarthropathie cascade van kinderen met haemophilie.From1 Oct 2014 → 30 Sep 2016Funding: BOF - Other initiatives
- (Epi)Genetic studies and system biology approaches to characterize rare inherited bleeding and platelet disorders: from patient studies to basic biology to cl inical applicationsFrom1 Oct 2014 → 30 Sep 2018Funding: BOF - Concerted Research Project from 1994
Publications
81 - 90 of 108
- Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene(2014)
Authors: Christophe Vandenbriele, Kathelijne Peerlinck, Thomy de Ravel de l'Argentière, Peter Verhamme, Thomas Vanassche
Pages: 139 - 141 - Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial.(2013)
Authors: Lieve Goossens, Philip Moons, Johny Verschakelen, Kathelijne Peerlinck, Marc Jacquemin
Pages: 1892 - 1899 - Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump(2013)
Authors: Steven Jacobs, Filip Rega, Kathelijne Peerlinck, Marc Jacquemin, Johan Vanhaecke, Johan Van Cleemput, Bart Meyns
Pages: 539 - 45 - Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory(2013)
Authors: Jaan Toelen, Kathelijne Peerlinck, Marc Jacquemin
Pages: E133 - E138 - Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A(2013)
Authors: Kathelijne Peerlinck
Pages: 1954 - 1962 - Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation(2013)
Authors: Christophe Vandenbriele, Thomas Vanassche, Marijke Peetermans, Peter Verhamme, Kathelijne Peerlinck
Pages: 121 - 123 - Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters(2013)
Authors: Peter Verhamme, Kathelijne Peerlinck
Pages: 744 - 752 - Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement A randomised, controlled trial(2013)
Authors: Peter Verhamme, Kathelijne Peerlinck, Thomas Vanassche, Christophe Vandenbriele
Pages: 1091 - 1098 - Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII(2012)
Authors: Marc Jacquemin, Kathelijne Peerlinck, Thomas Vanassche, Marc Hoylaerts, Peter Verhamme
Pages: 1371 - 1378 - Catheter-directed thrombolysis with microplasmin for acute peripheral arterial occlusion (PAO): an exploratory study(2012)
Authors: Peter Verhamme, Sam Heye, Kathelijne Peerlinck, Inge Fourneau, Kim Daenens, Ann Belmans, Geert Maleux
Pages: 289 - 296